Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison-Reference-Cited by-同舟云学术

Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison

Published:2021-10 Issue: Volume:78 Page:98-103
ISSN:0899-7071
Container-title:Clinical Imaging
language:en
Short-container-title:Clinical Imaging

Author:

Tosun Mesude,Uslu Hande

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging

Reference33 articles.

1. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries;Wong;Eur Urol,2016

2. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study;Ahmed;Lancet,2017

3. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature;Fütterer;Eur Urol,2015

4. Prostate imaging reporting and data system version 2.0;American College of Radiology,2016

5. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer;Catalona;N Engl J Med,1991

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer;Chemical & Biomedical Imaging;2024-06-11

2. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer;JAMA Network Open;2024-03-29

3. Infectious Disease Physician Availability and Postgraduate Antimicrobial Stewardship Education in Japan;JAMA Network Open;2024-03-29

4. Correlation Analysis between Apparent Diffusion Coefficient of Prostate Cancer and other Prostate Cancer Indicators;Iranian Red Crescent Medical Journal;2023-04-29

5. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218;Investigative Radiology;2022-05-05